Transurethral Ultrasound Ablation (TULSA)
Robert Princenthal, MD, describes the transurethral ultrasound ablation (TULSA) procedure, highlighting its flexibility, effectiveness, and histological benefits.
Read More
2022
Men’s Health & My World from A-to-Z: What is New, Old, Hot, or Cold?
Mark A. Moyad, MD, MPH, the Jenkins/Pokempner Director of Preventive/Complementary and Alternative Medicine (CAM) in the Department of Urology at the University of Michigan Medical Center in Ann Arbor, Michigan, reports on the latest trends in men’s health and related research. Covering topics from blood pressure to vitamin D, Dr. Moyad brings levity to the array with a “hot or not” rating.
Read More
Practical Applications and Clinical Utility of PYLARIFY Injection: Implications for Urology and Radiation Oncology
Phillip J. Koo, MD, Division Chief of Diagnostic Imaging and Northwest Region Oncology Physician Executive at the Banner MD Anderson Cancer Center in Phoenix, Arizona, discusses the expansion of the role and utility of prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in the management of prostate cancer. He highlights the fact that this next-generation imaging (NGI) technology will lead to changes to diagnostic approach and management, explaining that a landscape change is imminent as NGI is poised to fundamentally change the medical management of prostate cancer.
Read More
Distractions and the Doctor-Patient Relationship
Grand Rounds in Urology Contributing Editor Neil H. Baum, MD, Professor of Urology at Tulane Medical School, presents on the impact distractions have on the doctor-patient relationship. Dr. Baum reviews data on the role distracted driving plays in fatal car crashes before drawing a parallel to distractions in the exam room. He concludes that physicians should avoid and eliminate distractions in their practice by using technology to avoid data entry during an exam and setting criteria for permissible interruptions.
Read More
Utilization of Focal Therapy for Patients Discontinuing Active Surveillance of Prostate Cancer: Recommendations of an International Delphi Consensus
In this 21-minute presentation, Thomas J. Polascik, MD, FACS, Professor of Surgery at Duke University and Director of Surgical Technology at the Duke Prostate and Urological Cancer Center, posits that patients discontinuing active surveillance (AS) for prostate cancer may be good candidates for focal therapy (FT) rather than radical therapy, describing an international Delphi Consensus on the issue. Eighty-seven percent of respondents agreed that there is a role for FT for men coming off AS, citing the fact that FT is less invasive, has a greater likelihood of preserving both urinary continence and erectile function, comes with fewer side effects, and has an earlier recovery post-treatment as part of the rationale for recommending FT over radical therapy for men discontinuing AS with an imageable, biopsy-confirmed, localized cancer.
Read More